前列腺癌最新进展：2005年
Prostate cancer update: 2005.
作者信息
Ryan Charles J, Small Eric J
机构信息
Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
出版信息
Curr Opin Oncol. 2006 May;18(3):284-8. doi: 10.1097/01.cco.0000219259.83585.f3.
PURPOSE OF REVIEW
The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer that have been published in the medical literature in the past year.
RECENT FINDINGS
Recent research has shown that prostate specific antigen (PSA) velocity can be utilized as a prognostic tool in patients with localized prostate cancer and at the time of serologic relapse. Several novel biomarkers are, however, demonstrating encouraging results in refining or replacing PSA as a screening and prognostic tool. A number of studies have shown that dose and dose intensity of radiation have important ramifications.
SUMMARY
Recent data reported in the past year have significant implications in screening and diagnosis of prostate cancer as well as the management of localized prostate cancer with radiation.
综述目的
本综述的目的是突出过去一年在医学文献中发表的前列腺癌诊断、预防和管理方面最重要的进展。
最新发现
最近的研究表明，前列腺特异性抗原（PSA）速度可作为局限性前列腺癌患者和血清学复发时的预后工具。然而，一些新型生物标志物在完善或取代PSA作为筛查和预后工具方面显示出令人鼓舞的结果。多项研究表明，放疗的剂量和剂量强度具有重要影响。
总结
过去一年报道的最新数据对前列腺癌的筛查和诊断以及局限性前列腺癌的放疗管理具有重要意义。
Zotero 插件